MUC1 and non-small cell lung carcinoma: Additionally, the L-BLP25 vaccine, which consists of a 25 amino acid sequence (STAPPAHGVTSAPDTRPAPGSTAPP) derived from MUC1, the BL25 fat peptide, the TLR4 (Toll-like receptor4) agonist monophosphoryl lipid A (MPLA), and three lipid A adjuvants, has been shown to activate peripheral blood lymphocytes and to induce strong Cytotoxic T-Lymphocyte (CTL) responses in Phase III clinical trials involving NSCLC patients (276, 285).